Abstract
Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).
Original language | English |
---|---|
Journal | Diabetes Care |
Volume | 33 |
Issue number | 11 |
Pages (from-to) | 2304-9 |
Number of pages | 6 |
ISSN | 0149-5992 |
DOIs | |
Publication status | Published - 1 Nov 2010 |